IDH1 and central nervous system cancer: Variations in glioma survival and response to therapy are ascribed to genetic and histological characteristics, particularly the degree of isocitrate dehydrogenase (IDH) mutation, the presence of 1p/19q co-deletion, and the tumor grade (2–4).